Effect of ethanolic seed extract of Mucuna pruriens (L.)DC.var.utilis on haloperidol induced tardive dyskinesia in rats

International Journal of Pharmaceutical Sciences Review and Research

Volumn 3, Issue 2, 2010, Pages 106-113

  Sivaraman, Dhanasekaran ^a   Ratheesh kumar, K S ^b   Muralidaran, Palayan ^a  

^a C L BAID METHA COLLEGE OF PHARMACY   (India)

^b WOLLO UNIVERSITY   (Ethiopia)

Author keywords

Antioxidant enzyme; Dopamine; Glutamate; Haloperidol; Mucuna pruriens; Tardive dyskinesia

Indexed keywords

ALCOHOL; CATALASE; DOPAMINE; GLUTAMIC ACID; GLUTATHIONE; HALOPERIDOL; HERBACEOUS AGENT; MUCUNA PRURIENS EXTRACT; PLANT EXTRACT; PROTEIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; COGNITION; CONTROLLED STUDY; DISSECTION; FEMALE; IN VIVO STUDY; LATENT PERIOD; LIPID PEROXIDATION; LOCOMOTION; MALE; MASTICATION; MAZE TEST; NONHUMAN; OROFACIAL DYSKINESIA; PHYTOCHEMISTRY; PLANT SEED; RAT; SPECTROFLUOROMETRY; TARDIVE DYSKINESIA; TONGUE SWELLING; TOXICITY TESTING;

EID: 79952024003     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Vaidya RA, Sheth AR, Aloorkar SD, Rege NR, Bagadia VN, Devi PK, Shah LP. The inhibitory effect of the cowhage plant-Mucuna pruriens-and Ldopa on chlorpromazine-induced hyperprolactinaemia in man. Neurol India. 1978; 26(4):177-8.
2. Hussain G, Manyam BV. Mucuna pruriens proves more effective than L-DOPA in Parkinson's disease animal model. Phytother Res 1997; 11: 419-423.
3. Manyam BV, Dhanasekaran M, Hare T. Neuroprotective effects of antiparkinson drug Mucuna pruriens. Phytother Res. 2004; 18: 706-712.
4. Yamini B. Tripathi and Anil K. Upadhyay. Effect of Alcohol Extract of the Seeds of Mucuna pruriens on Free Radicals and Oxidative Stress in Albino Rats. Phytother. Res 2002;16, 534-538
5. Pant MC, Joshi LD. Identification of pharmacologically active substance in the seeds of Mucuna pruriens DC. Indian J pharmacol 1970; 2: 24-29.
6. Kane JM and JM Smith. Tardive dyskinesia: prevalence and risk factors. Arch. Gen. Psychiatry.1982; 39, 473-481.
7. Egan MT, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, Blum A, Saez RE, Wyatt RJ. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry.1992; 149:773-777.
8. Trease GE and Evans WC. In phenols and phenolic glycosides.Text book of Pharmacognosy, London, ELBS, 1989; 223-249.
9. Donald Ecobichon J. The Basis of Toxicity Testing, NewYork, CRC press, 1997; 43-49.
10. Naidu S, Singh A, Kulkarni SK. Quercetin, a bioflavanoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology 2003; 44:1100-1106
11. Bishnoi M, Chopra K, Kulkarni SK. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical changes associated with an animal model of tardive dyskinesia. Pharmacological Reports 2007; 59:181-191.
12. Marklund S, Marklund G. Involvement of superoxide anion radical in the autoxidation of pyrogallol and a convenient assay of superoxide dismutase. Eur.J.Biochem 1974; 47: 469-474.
13. Marklund S, Marklund G. Involvement of superoxide anion radical in the autoxidation of pyrogallol and a convenient assay of superoxide dismutase. Eur.J.Biochem 1974; 47: 469-474.
14. Luck H. Methods of enzymatic analysis edited by Hans Ulrich Bergmeyer. 2nd Ed. Academic press New York and London. 1965: 885-890.
15. Okhawa H, Ohishi N, Yagi K. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical biochemistry 1979; 95: 351-358.
16. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione stransferase activities in rat lung and liver. Biochimica et Biophysica Acta 1979; 582:67-78
17. Lowry O.H, rosenbrough N.J, Farr A.L, Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265-275
18. Bernt E, Bergmeyer HU.L-Glutamate UV-Assay with glutamate dehydrogenase and NAD.Methods of enzymatic analysis edited by Hans Ulrich Bergmeyer.2nd Ed.Academic press New York and London 1965; 1704-1708.
19. Schlumpf M, Lichtensteiger W, Langemann H, Waser PG, Hefti F. A fluorimetric micromethod for the simultaneous determination of serotonin, noradrenaline and dopamine in milligram amount of brain tissue. Biochemical pharmacology 1974; 23:2337-2446.
20. Peet M, Langharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol.1993; 8: 151-153
21. Shivakumar BR, Ravindranath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther.1993; 265: 1137-1141
22. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radical and treatment with vitamin E. Schizophr Bull.1999; 25:731-740
23. Sagara Y. Introduction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 1998; 71:1002-1012.
24. Nielsen E.B, Lyon M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology 1978;59:85-89.
25. Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants of schizophrenia. Prostagland Leukotri Essent Fatty Acids.1996; 55: 45-54.
26. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science1976; 192:481-483.
27. Ravindranath. V, Reed D.J. Glutathione depletion and formation of glutathione protein mixed disulfide following expose of brain mitochondria to oxidative stress. Biochem. Biophys. Res. Commun 1990; 169, 150-158.
28. Parikh V, Mohammad Khan M, Sahebarao Mahadik P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psych Res 2003; 37: 43-51.
29. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxy alkenal, malondialdehyde and related aldehydes. Free Radic Biol Med 1991; 11:81-128.
30. Yao JK, Reddy R, Elhinny LG, Vankammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res1998; 32:385-391.
31. Banaclocha M. N Acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson's disease. Brain Res 2000; 850: 173-175.
32. Burger MBE, Fachineto R, Alves, Callegari L, Rocha JBT: Acute reserpine and sub-chronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 2005; 1031:202-210.
33. Andia I, Zumarraga M, Retuerto F, Zamalloa I, Davila T: Chronic neuroleptic treatment does not suppress the dynamic characteristics of the dopaminergic receptor D2 system. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:181-191.
34. Chu CY, Liu YL, Chiu HC, Jee SH: Dopamineinduced apoptosis in human melanocytes involves generation of reactive oxygen species. Br J Dermatol 2006; 154: 1071-1079.
35. Rosengarten H and D Quatermain. The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen month-old rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2002; 26:1047-1054.
36. M.N. Poornachandra, Salma Khanam, B.G. Shivanandda, T.N. Shivananda and R. Dris. Mucuna pruriens (L.)DC- A novel drug for learning and memory retrieval. Journal of Food, Agriculture & Environment 2005;3 (4):13-15
37. Dan J. Stein, David J. Kupfer, Alan F. Schatzberg. The American Psychiatric Publishing textbook of mood disorders, 2005.